Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Antoni C, Kavanaugh A, Kirkham B, et al. (2003) The one year results of the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 48: 265–266
Antoni E, Kavanaugh A, Gladman D et al. (2004) The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Arthritis Rheum; 50(suppl): ACR, abstr. 1135
Bruce IN, Gladman DD (1998) Psoriatic arthritis. Recognition and management. Bio Drugs 9: 271–278
Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT, McInnes IB (2000) Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 43: 1244–1256
Espinoza LR, Zakraoui L, Espinoza CG, Gutierrez F, Jara LJ, Silveira LH, Cuellar ML, Martinez-Osuna P (1992) Psoriatic arthritis: clincal responses and side effects to methotrexate therapy. J Rheumatol 12: 872–877
Gladman DD, Farewell VT (1995) The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Arthritis Rheum 38: 845–850
Gladman DD, Farewell VT, Nadeau C (1995) Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 22: 675–679
Gladman DD, Farewell VT, Wong K, Husted J (1998) Mortality studies in psoriatic arthritis. Results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41: 1103–1110
Harrison BJ, Silman AJ, Barrett EM, Scott DG, Symmons DP (1997) Presence of psoriasis does not influence the presentation or short term outcome of patients with early inflammatory polyarthritis. J Rheumatol 24: 1744–1749
Leczinsky CG (1948) The incidence of arthropathy in a ten-year series of psoriasis cases. Acta Dermato venerol 28: 483–487
Marsal S, Armadans-Gil L, Martinez M, Gallardo D, Ribera A, Lience E (1999) Clinical, radiographic and HLA associations as markers of different patterns of psoriatic arthritis. Br J Rheumatol 38: 332–337
Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etancercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356: 385–390
Menter MA, Gordon KB, Leonardi C et al. (2004) Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis with and without PsA. Arthritis Rheum 50(suppl): ACR 2004, abstr. 1622 [Finde ich nicht veröffentlicht]
Moll JMH, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3: 55–78
Scarpa R, Oriente P, Pucino A, Torella M, Vignone L, Riccio A, Biondi Oriente C (1984) Psoriatic arthritis in psoriatic patients. Br J Rheumatol 23: 246–520
Veale D, Rodgers S, Fitzgerald D (1994) Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 33: 133–138
Wang Q, Vasey FB, Mahfood JP, Valeriano J, Kanik KS, Anderson BE, Bridgeford PH (1999) V2 regions of 16S ribosomal RNA used as a molecular marker for the species identification of streptococci in peripheral blood and synovial fluid from patients with psoriatic arthritis. Arthritis Rheum 42: 2055–2059
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 2005 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Schewe, S. (2005). Psoriasis-Arthritis. In: Plewig, G., Kaudewitz, P., Sander, C.A. (eds) Fortschritte der praktischen Dermatologie und Venerologie. Fortschritte der praktischen Dermatologie und Venerologie, vol 19. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-28691-8_35
Download citation
DOI: https://doi.org/10.1007/3-540-28691-8_35
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-21055-9
Online ISBN: 978-3-540-28691-2
eBook Packages: Medicine (German Language)